Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. - Test2 - elhamkhani - TriplyDB

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.

http://www.wikidata.org/entity/Q33259359

about

Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy Epigenetic therapy in gastrointestinal cancer: the right combination Epigenetics in non-small cell lung cancer: from basics to therapeutics Trials with 'epigenetic' drugs: an update DNA demethylation and invasive cancer: implications for therapeutics Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report Targeting the epigenome in malignant pleural mesothelioma Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.Targeting DNA methylation for epigenetic therapy.The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.Epigenetic regulation of prostate cancer RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.Epigenetic therapy in lung cancer.DNA methylation: its role in cancer development and therapy.Expression of cancer/testis antigens is correlated with improved survival in glioblastoma.Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance Molecular biological challenges in he treatment of esophageal adenocarcinoma.Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

P2860

Q24609974-84D89BEC-5F63-4A32-A4BC-948B82AF33F7 Q26745709-BC51BFE2-5A8A-41B5-8B8F-E1AC2DAD0DDC Q26749113-51D583F6-97E3-4E6E-BF3D-B2B30D21DEEA Q27000542-3D593D94-898D-49F5-8D40-1352CB46380F Q27011914-4A35C728-9EF4-4084-AED4-FB35E18900E4 Q28477252-B50BF6B1-2CC8-4AC9-8F60-8AC096AC2D9E Q28487027-ED3B26AC-AD35-4273-BF8F-2FEF16FD9ADB Q30974053-97E4E2AC-0894-42BD-88EF-FC7F4AB1F91A Q33390459-248F95B2-EC71-4C6A-9FEC-9F727F610B89 Q33416734-5F6FC115-BFC0-4497-9BAE-23C08C18956F Q33621141-CA230C21-E971-4C9F-879D-C325D787F82F Q33715446-1E230FB1-F0E8-4FC4-964D-5E49B003B9D8 Q33744733-37F52EEE-67DA-4710-ADA6-49E2D808A23B Q33890546-4D0ADEDA-BF50-4A17-AE26-26AC3FE106F2 Q33957165-3EC2A08F-8EDD-4D8D-B930-CA15AD206017 Q33980682-FF363A13-A493-40CA-8CB8-41F10D1FD4D2 Q34101643-B40E78C0-7FDE-40FC-8CAA-9C2E5F082710 Q34182308-DFA5F43B-CCFE-4D3F-B10D-052F4EFCEAC6 Q34258037-57BFB1C0-63AA-4A9D-84A2-57120B710E7B Q34717933-302B3EF2-C3FE-45C6-86CD-C77A07110C53 Q35050623-40DD1481-A843-4207-9804-1D324BC77CFC Q35229048-080C298D-647C-44C0-B7BA-616262FBC68D Q35851931-10F739BB-A952-4F45-9D70-10FECF36C2D8 Q36001910-3A9CEDCF-D4AC-41B7-B133-0B2A7A947464 Q36015018-E13CE831-5D2E-4F55-A23A-C6855B433AEE Q36136992-F5365028-237B-45C2-8D65-DB8E76BFF466 Q36214731-5A8712F5-95D1-4F7C-BC24-EF0421767EBA Q36238674-A8B0D944-3791-4DFC-BCFF-538CC01D8437 Q36287972-96732BA0-5379-4B29-AE48-906072E9923A Q36502385-B3EF4DFC-FA85-4B69-8E88-E5A138F00503 Q36638089-5680567C-B438-40E8-A1B3-6457D4FC147C Q36702401-92292648-E021-4E7E-AAE1-5F6865D9C5D6 Q36801625-5FFC226F-F097-475E-B75D-4CF64BC8CCF7 Q36885903-7FF95F04-AF5A-47B5-8577-6585226EC938 Q36986433-5F63E98D-7DA6-4F82-A4F4-BE7376B9DAAF Q37038420-91693BCE-68FC-4225-9FDF-A8FDC16E70A4 Q37197945-D5586325-737D-464D-902D-014265C5EA0B Q37287152-83D24BD5-4150-4097-AF6C-A773DFEAFADC Q37345996-A11706FE-BFD8-4885-8D65-D0CF5C6A6334 Q37444619-B07E60EC-3E31-4642-9FD7-CD98A37BE6A5

P2860

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.

http://www.wikidata.org/entity/Q33259359

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@ast

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@en

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@nl

type

label

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@ast

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@en

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@nl

prefLabel

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@ast

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@en

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@nl

P1433

Q33259359-1E63322A-42BA-4041-A79F-C38BA91A12CF

P1476

Q33259359-39DF3D76-4CEA-4F7F-97CA-3622C7F2BFA7

P2093

Q33259359-09C5A69A-C24C-4F3D-AEA4-EFE61C408923

Q33259359-1546AE04-E1D5-4945-AE55-082DD99C7848

Q33259359-248DA632-2E66-420C-9CB9-76FB203B5F24

Q33259359-2591043C-186F-4C34-B952-F2E3467D388F

Q33259359-32EA97B9-B5BC-446F-BA87-9E222F318D7F

Q33259359-481D081B-0194-4D11-A024-3FD8471D8122

Q33259359-61727087-F096-426E-B59F-21890D90D43E

Q33259359-70046B0A-B4C8-406C-889B-1F3F7336DA24

Q33259359-7896F5AC-391A-46DD-AE64-F35DDE616B19

Q33259359-837320D9-C56F-4DB8-B15B-CD714A69BBC8

P304

Q33259359-849FD0A3-DC2A-42D2-B852-73CB6EBE4CD0

P31

Q33259359-9662EA18-FAED-40DA-868E-ACFEA6E244F0

P356

Q33259359-BA33E262-4E65-4A71-AFCB-BB4A57D20D22

P407

Q33259359-89C81CE2-F304-45FD-ABD2-991EE554D0D7

P433

Q33259359-7676DDEF-DBEA-4D87-9443-C9912BD965E9

P478

Q33259359-24E6275B-A443-41BF-A054-DD416909E081

P577

Q33259359-CA0B9E0A-118B-4102-AA6E-CE64B6BF14DA

P5875

Q33259359-BECBD687-63C7-4085-804A-9C795F702B90

P698

Q33259359-3021C8D2-FA40-4CD7-A8A2-9F3BF63BD3DD

P921

Q33259359-73C81296-2C97-4BFB-9293-89E631749625

P356

1078-0432.CCR-06-0669

P1433

Clinical Cancer Research

P1476

Phase I study of decitabine-me ...... e lungs, esophagus, or pleura.

@en

P2093

Ana Hancox

http://www.w3.org/2001/XMLSchema#string

Anthony J Murgo

http://www.w3.org/2001/XMLSchema#string

Dao M Nguyen

http://www.w3.org/2001/XMLSchema#string

David S Schrump

http://www.w3.org/2001/XMLSchema#string

G Aaron Chen

http://www.w3.org/2001/XMLSchema#string

Julie A Hong

http://www.w3.org/2001/XMLSchema#string

Maria R Fischette

http://www.w3.org/2001/XMLSchema#string

Ming Zhao

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

Tricia F Kunst

http://www.w3.org/2001/XMLSchema#string

P304

5777-5785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-0669

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6774038

http://www.w3.org/2001/XMLSchema#string

P698

17020984

http://www.w3.org/2001/XMLSchema#string

P921